Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › Varivax

Varivax

0 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of Varivax

14 trials tracked of Varivax: 11 in phase 3 or 4 and 4 with published results. The most-cited published study has 42 citations.

14Trials tracked
11Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 3 11 Phase 2 2 Other / NA 1
  1. Phase 3 Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029) Completed · 42 cited
  2. Phase 3 Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2/V114-026) Completed · 21 cited
  3. Phase 3 A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION) Completed · 18 cited
  4. Phase 3 Evaluation of the Immunogenicity and Safety of VARIVAX™ in Healthy Russians (V210-058) Completed · 3 cited
  5. Phase 3 Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants Completed
  6. Phase 3 Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine Completed
Show 8 more trials
  1. Phase 3 Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age. Completed
  2. Phase 3 Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age Completed
  3. Phase 3 Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age Completed
  4. Phase 3 Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children Completed
  5. Phase 3 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life Completed
  6. Phase 2 Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate Vaccines Completed
  7. Phase 2 Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age Completed
  8. N/A Re-examination Study For Varivax (V210-059 AM2) Completed

Showing the 14 most-cited and recently-updated of 14 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
No published articles yet for this medication. Check back soon.